Plasma Fractionation Market Trends, Growth Insight, Size, Share, Competitive Analysis, Statistics, Regional, And Global Forecast To 2025
Plasma Fractionation Market Overview:
The Plasma Fractionation Market is expected to grow at a CAGR of 6.7 percent over the forecast period, from USD 28.6 billion in 2020 to USD 39.5 billion in 2025. Growing use of immunoglobulins in various therapeutic domains, increased plasma collection (and the number of plasma collection facilities), expanding elderly population, and rising prevalence of respiratory disorders and alpha-1-antitrypsin deficiency are all driving market expansion (AATD). However, during the forecast period, the high cost of plasma products, limited reimbursements, and the advent of recombinant alternatives are projected to hamper the market's growth to some extent.
OPPORTUNITY: Rising prevalence of bleeding disorders
Hemophilia, often known as haematological diseases, is one of the most common uses for plasma fractionation products. Hemophilia is a genetic bleeding illness characterised by reduced blood coagulation due to a lack of coagulation factor VIII synthesis or action. According to the World Federation of Hemophilia, there were 167,110 haemophilia patients globally in 2011, up 25.9% to 210,454 individuals in 2018. Only 30% of people are diagnosed with haemophilia, and only 25% of those identified receive therapy. The majority of persons with haemophilia go undetected, and approximately 75% of patients receive ineffective or no therapy at all.
Request For Sample:
COVID-19 impact on the plasma fractionation market
COVID-19 is an infectious disease caused by the recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan, China, in December 2019, COVID-19 has moved from a regional crisis to a global pandemic. The World Health Organization (WHO) officially declared the outbreak of COVID-19 a pandemic in March 2020. A number of established pharmaceutical and biopharmaceutical companies, as well as small startups, have stepped forward to develop treatments that target the infection caused by the novel coronavirus. Although, no specific drugs have been approved yet for its treatment, based on the positive findings of a number of clinical trials, convalescent plasma (CP) therapy is expected to increase the survival rate of COVID-19 patients. Hence, federal agencies of various countries such as the US and India are taking initiatives to offer this therapy to patients as quickly as possible, while at the same time conducting the clinical trials to find out the safety and effectiveness of the therapy. For instance,
The pulmonology segment is expected to grow at the highest CAGR during the forecast period
Based on application, the plasma fractionation market is segmented into neurology, immunology, hematology, critical care, pulmonology, hemato-oncology, rheumatology, and other applications. In 2019, the pulmonology segment is expected to register the highest CAGR during the forecast period. Growth in this market segment is driven largely by the rising prevalence of alpha-1 antitrypsin deficiency and chronic obstructive pulmonary disease (copd).
North America was the largest regional market for plasma fractionation market in 2019
The global plasma fractionation market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2019, North America accounted for the largest share of the plasma fractionation market, followed by Europe and the Asia Pacific. The large share of North America in the global market is attributed to the growing use of immunoglobulins in various therapeutic areas, growing geriatric population, and the increasing prevalence of respiratory diseases and AATD. However, the market in the Asia Pacific is expected to grow at the highest CAGR during the forecast period. This can be attributed to the growth in the overall healthcare industry, increasing number of hemophilic patients, increasing number of organ transplantations, increasing focus on diagnosis and prophylactic treatment, increasing awareness about technologically advanced products, and improving the standard of living in several APAC countries.
Key players in the global plasma fractionation market include CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), and BPL (UK), Sanquin (Netherlands),
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model — GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledgestore” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062